Postoperative Pain Alleviation in Open Heart Surgery
1 other identifier
interventional
90
1 country
1
Brief Summary
Effective pain relief after cardiac surgery has assumed importance with the introduction of fast track discharge protocols that requires early weaning from mechanical ventilation. Inadequate pain control reduces the capacity to cough, mobility, increases the frequency of atelectasis, and prolongs recovery. Infiltration of local anesthetics near the surgical wound has shown to improve early postoperative pain in various surgical procedures. Magnesium is the fourth most plentiful cation in our body. It has antinociceptive effects in animal and human models of pain.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jul 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedFirst Submitted
Initial submission to the registry
April 4, 2017
CompletedFirst Posted
Study publicly available on registry
April 10, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2017
CompletedNovember 22, 2017
November 1, 2017
8 months
April 4, 2017
November 21, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
postoperative pain
Vas Scale
48 hours postoperative
Secondary Outcomes (2)
extubation time
48 hours
Fentanyl consumption
48 hours
Study Arms (3)
group A
ACTIVE COMPARATOR( bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
group B
ACTIVE COMPARATORbupivacaine 0.125% infusion in the presternum , for 48 hours
Group C
ACTIVE COMPARATORwill be conventional , will receive postoperative fentanyl , paracetamol , and ketorolac.
Interventions
will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
will receive bupivacain 0.125% infusion in the presternum , for 48 hours
only conventional post operative analgesics will be used
Eligibility Criteria
You may qualify if:
- years old
- American Society of Anesthesiologists physical status II and III
- Patients scheduled for open heart valve replacement surgery with sternotomy
You may not qualify if:
- Emergency surgery
- Clinically significant kidney or liver disease
- Patients allergic to local anesthetic
- Patients with prolonged CPB time (\>120 min)
- Patients required intra-aortic balloon pump
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Emad Zarief Kamel Said
Asyut, 71111, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Emad Kamel Said, MD
Anesthesia departement , Faculty of Medicine , Assiut university
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- lecturer of anesthesia and ICU
Study Record Dates
First Submitted
April 4, 2017
First Posted
April 10, 2017
Study Start
July 1, 2016
Primary Completion
March 1, 2017
Study Completion
July 1, 2017
Last Updated
November 22, 2017
Record last verified: 2017-11
Data Sharing
- IPD Sharing
- Will not share